

Anti-Goat IgG (H&L) (Rhodamine Conjugated) Pre-Adsorbed Secondary Antibody

Rabbit Polyclonal, Rhodamine (TRITC) Catalog # ASR2026

Product Information

Description Anti-GOAT IgG (H&L) (RABBIT) Antibody Rhodamine Conjugated (Min X

Human Serum Proteins)

Host Rabbit

Conjugate Rhodamine (TRITC)

FP Value 2.8 moles Rhodamine (TRITC) per mole of IgG

Target SpeciesGoatClonalityPolyclonalPhysical StateLyophilizedHost IsotypeIgG

Target Isotype IgG (H&L)

Buffer 0.02 M Potassium Phosphate, 0.15 M Sodium Chloride, pH 7.2

Immunogen Goat IgG whole molecule

Reconstitution Volume 1.0 mL

Reconstitution Buffer Restore with deionized water (or equivalent)

Stabilizer 10 mg/mL Bovine Serum Albumin (BSA) - Immunoglobulin and Protease free

Preservative 0.01% (w/v) Sodium Azide

Additional Information

Shipping Condition Ambient

Purity This product was prepared from monospecific antiserum by immunoaffinity

chromatography using Goat IgG coupled to agarose beads followed by solid

phase adsorption(s) to remove any unwanted reactivities. Assay by

immunoelectrophoresis resulted in a single precipitin arc against anti-Rabbit Serum, Goat IgG, and Goat Serum. No reaction was observed against Human

Serum Proteins.

Storage Condition Store vial at 4° C prior to restoration. For extended storage aliquot

contents and freeze at -20° C or below. Avoid cycles of freezing and thawing. Centrifuge product if not completely clear after standing at room temperature. This product is stable for several weeks at 4° C as an undiluted

liquid. Dilute only prior to immediate use.

Precautions NoteThis product is for research use only and is not intended for therapeutic or

diagnostic applications.

Background

This product is designed for immunofluorescence microscopy, fluorescence based plate assays (FLISA) and

fluorescent western blotting. This product is also suitable for multiplex analysis, including multicolor imaging, utilizing various commercial platforms.

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.